title: Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
abstract: Doxorubicin (DOX)-loaded glycyrrhetinic acid (GA)-modified alginate (ALG) nanoparticles (DOX/GA-ALG NPs) were prepared for targeting therapy of liver cancer. This study focused on the biodistribution of DOX/GA-ALG NPs in Kunming mice as well as their antitumor activity against liver tumors in situ and side effects. The biodistribution data showed that the concentration of DOX in the liver reached 67.8 ± 4.9 μg/g after intravenous administration of DOX/GA-ALG NPs, which was 2.8-fold and 4.7-fold higher compared to non-GA-modified nanoparticles (DOX/CHO-ALG NPs) and DOX·HCl, respectively. The concentration of DOX in the heart of mice treated with DOX/GA-ALG NPs at any sampling time was relatively lower than that of mice treated with DOX·HCl. The liver tumor growth inhibition rate (IR) in situ was about 52.6% and the mortality was 33% in DOX·HCl group. In contrast, the IR was 76.6% and no mice died in the DOX/GA-ALG NPs group. Histological examination showed tumor necrosis in both experimental groups. Most importantly, the heart cells and the liver cells surrounding the tumor were not affected by administration of DOX/GA-ALG NPs, whereas myocardial necrosis and apparent liver cell swelling were observed after DOX·HCl administration.
authors.affiliation: Key Laboratory of Functional Polymer Materials, Ministry of Education, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, PR China.
authors.forename: Chuangnian
authors.initials: C
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Tong
authors.initials: T
authors.lastname: Liu
authors.forename: Yukun
authors.initials: Y
authors.lastname: Wu
authors.forename: Hua
authors.initials: H
authors.lastname: Guo
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Qin
authors.initials: Q
authors.lastname: Tian
authors.forename: Yongming
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yuan
mesh_terms: D000464:Alginates / Q000737:chemistry*; D000818:Animals; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D020723:Glucuronic Acid / Q000737:chemistry; D006034:Glycyrrhetinic Acid / Q000737:chemistry* / Q000378:metabolism; D006603:Hexuronic Acids / Q000737:chemistry; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008422:Materials Testing; D051379:Mice; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry*; D014018:Tissue Distribution
chemical_list: D000464:Alginates; D004337:Drug Carriers; D006603:Hexuronic Acids; D004317:Doxorubicin; D020723:Glucuronic Acid; D006034:Glycyrrhetinic Acid